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Abstract Ghrelin is an endogenous ligand of the growth hor-
mone secretagogue receptor (GHS-R), which has been originally
isolated from rat stomach. Evidence has been previously pro-
vided that adrenal gland possesses abundant ghrelin-displaceable
GHS-Rs, but nothing is known about the possible role of ghrelin
in the regulation of adrenocortical function. Reverse transcrip-
tion-polymerase chain reaction demonstrated the expression of
ghrelin and GHS-R in the rat adrenal cortex, and high adrenal
concentrations of immunoreactive ghrelin were detected by ra-
dioimmune assay (RIA). Autoradiography localized abundant
[125I]ghrelin binding sites in the adrenal zona glomerulosa
(ZG) and outer zona fasciculata (ZF). Ghrelin (from 10310 to
1038 M) did not a¡ect either basal steroid hormone (pregneno-
lone, progesterone, 11-deoxycorticosterone, corticosterone, 18-
hydroxycorticosterone and aldosterone) secretion from dispersed
ZG and zona fasciculata/reticularis (ZF/R) cells (as evaluated
by quantitative high pressure liquid chromatography), or basal
and agonist-stimulated aldosterone and corticosterone produc-
tion from cultured ZG and ZF/R cells, respectively (as mea-
sured by RIA). Ghrelin (1038 and 1036 M) raised basal, but
not agonist-stimulated, proliferation rate of cultured ZG cells
(percent of cells able to incorporate 5-bromo-2P-deoxyuridine),
without a¡ecting apoptotic deletion rate (percent of cells able to
incorporate biotinylated nucleosides into apoptotic DNA frag-
ments). The tyrosine kinase (TK) inhibitor tyrphostin-23 and the
p42/p44 mitogen-activated protein kinase (MAPK) inhibitor
PD-98059 abolished the proliferogenic e¡ect of 1038 M ghrelin,
while the protein kinase A and C inhibitors H-89 and calphos-
tin-C were ine¡ective. Ghrelin (1038 M) stimulated TK and
MAPK activity of dispersed ZG cells, and the e¡ect was abol-
ished by preincubation with tyrphostin-23 and PD-98059,
respectively. Tyrphostin-23 annulled ghrelin-induced activation
of MAPK activity. Taken together, the present ¢ndings indicate
that (i) ghrelin and GHS-R are both expressed in the rat adre-
nal cortex, ghrelin binding sites being very abundant in the ZG;
(ii) ghrelin does not a¡ect the secretory activity of rat adreno-
cortical cells, but signi¢cantly enhances the proliferation rate of
cultured ZG cells, without a¡ecting apoptotic deletion rate;
and (iii) the ZG proliferogenic action of ghrelin involves the
TK-dependent activation of the p42/p44 MAPK cascade.
> 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Ghrelin is a 28 amino acid peptide, originally isolated from
rat stomach, which acts as an endogenous ligand of the
growth hormone (GH) secretagogue receptor (GHS-R) [1],
two subtypes of which have been identi¢ed: the fully func-
tional GHS-R1a and the biologically inactive GHS-R1b [2,3].
Ghrelin and GHS-Rs are expressed in the hypothalamus [4],
abundant ghrelin binding sites are present in the pituitary
gland [5], and the main biological e¡ects of ghrelin known
to date are exerted on the hypothalamo-pituitary complex.
Ghrelin, in addition to eliciting pituitary GH release [1,6,7],
exerts an orexinogenic action [8^10] and is possibly involved
in the neuroendocrine and behavioral responses to stresses
via its stimulating e¡ect on the hypothalamic adrenocortico-
tropic hormone (ACTH) secretagogues CRH and vasopressin
[11^13].
Evidence has been provided that ghrelin is expressed in
some endocrine tissues, like human and rat pancreatic islets
and rat Leydig cells [14,15], where it stimulates insulin release
and inhibits agonist-enhanced testosterone secretion, respec-
tively. Human adrenal glands were found to possess abundant
ghrelin-displaceable GHS-Rs [16], and to express both ghrelin
and GHS-R1a mRNAs [17]. Recent ¢ndings indicate that rat
adrenals, although not expressing ghrelin mRNA, are pro-
vided with GHS-R1a. However, ghrelin was unable to exert
any appreciable e¡ect on basal and ACTH-stimulated corti-
costerone secretion from quarters of the entire gland [18]. This
last observation does not rule out the possibility that ghrelin
a¡ects the secretion of hormones other than corticosterone,
e.g. aldosterone produced by zona glomerulosa (ZG). More-
over, it could be possible that GHS-Rs may be involved in the
control of rat adrenal growth. Thus, the present study was
undertaken to investigate (i) the ghrelin and GHS-R expres-
sion in the rat adrenal cortex, (ii) the zonal localization of
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ghrelin binding sites, and (iii) the ghrelin e¡ects on secretion
and growth of rat adrenocortical cells cultured in vitro.
2. Materials and methods
2.1. Animals and reagents
Adult male Sprague^Dawley rats (260I 30 g body weight) were
purchased from Charles-River (Como, Italy), and the protocol of
the experiment was approved by the local Ethics Committee for Ani-
mal Studies. Rats were decapitated, and their adrenal glands were
promptly removed and cleaned from adherent adipose tissue. Hypo-
thalamus and testis were also removed from some animals.
Rat ghrelin was purchased from Neosystem Laboratoires (Stras-
bourg, France), [125I]ghrelin from Phoenix Pharmaceuticals (Belmont,
CA, USA), and His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lis-NH2 (hexare-
lin) from Peninsula Laboratories (St. Helens, UK). Anti-p42/p44 anti-
body was provided by Santa Cruz Biotechnology (Santa Cruz, CA,
USA), Dulbecco’s modi¢ed Eagle’s minimum essential medium
(DMEM) by Gibco (Paisley, UK), Medium 199 by Difco (Detroit,
MI, USA), and cyanoketone (WIN-24540) by Sterling-Winthrop
(Guilford, UK). H-89, calphostin-C, tyrphostin-23 and PD-98059
were obtained from Biomol (Milan, Italy). Endothelin-1[1^31] (ET-
1[1^31]) was purchased from Peptide Institute (Osaka, Japan). ACTH,
angiotensin-II (Ang-II), 5P-bromo-2P-deoxyuridine (BrdU), bovine se-
rum albumin (BSA), human serum albumin (HSA), fetal calf serum
(FCS) and all other chemicals and laboratory reagents were obtained
from Sigma Chemical Company (St. Louis, MO, USA).
2.2. Reverse transcription-polymerase chain reaction (RT-PCR)
RNA was extracted from the adrenal cortex (enucleated adrenal
gland), hypothalamus and testis of six rats with the guanidium iso-
thiocyanate method, and total RNA was reverse transcribed to cDNA
[15]. PCR procedures followed those described earlier [19], and the
sense and antisense primers for ghrelin and GHS-R were selected
according to Tene-Sempere et al. [15]. GHS-R primers were £anking
a coding area common to both GHS-R1a and GHS-R1b splice var-
iants [18]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
chosen as housekeeping gene. In a thermal cycler (Delphi 100; Oracle
Biosystems, MJ Research, Waterston, MA, USA), after an initial step
at 97‡C for 5 min, we used a denaturation step at 96‡C for 90 s, an
annealing step for 90 s, and an extension step at 72‡C for 3 min for a
total of 36 cycles. An additional extension step at 72‡C for 10 min was
then carried out. Primer sequences, annealing temperature and the
predicted size of PCR products are shown in Table 1. To rule out
the possibility of amplifying genomic DNA, one PCR was carried out
without prior RT of the RNA. Detection of the PCR ampli¢cation
products was ¢rst performed by size fractionation on 2% agarose gel
electrophoresis. Then, after puri¢cation using the QIA quick PCR
puri¢cation kit (Qiagen, Hilden, Germany), amplicons were identi¢ed
by sequencing (Alf Sequencer; Pharmacia Biotech, Freiburg, Ger-
many).
2.3. Ghrelin radioimmune assay (RIA)
Adrenal cortex, hypothalamus and testis of six rats were homoge-
nized in phosphate-bu¡ered saline (PBS), and their protein concentra-
tion was determined by the Lowry method, using BSA as a standard.
Ghrelin was separated and puri¢ed by chromatography, using a Sep-
Pak C18 cartridge (Waters, Milford, MA, USA), and its concentra-
tion in eluates was determined using the ghrelin (rat) RIA kit of
Phoenix Pharmaceuticals (sensitivity: IC50, 7.2 fmol/tube; intra- and
interassay CVs: 6.3 and 8.5%, respectively).
2.4. Autoradiography
Adrenal glands of three rats were immediately frozen at 330‡C by
immersion in isopentane, and stored at 380‡C. Frozen sections (10^
15 Wm thick) were cut in a cryostat (Leitz 1720 Digital) at 320‡C, and
processed for autoradiography as previously detailed [20]. They were
labeled in vitro by incubation for 120 min at 37‡C with 1038 M
[125I]ghrelin, and the selectivity of binding was checked by addi-
tion of 1036 M cold ghrelin or 1037 M hexarelin. The reaction was
stopped by washing the samples three times in 50 mM Tris^HCl bu¡-
er. After rinsing, the sections were rapidly dried, ¢xed in paraformal-
dehyde vapors at 80‡C for 120 min, and coated with NTB2 nuclear
emulsion (Eastman Kodak, Rochester, NJ, USA). Autoradiographs
were exposed for 2 weeks at 4‡C, and then developed with undiluted
Kodak D19 developer. They were stained with hematoxylin-eosin, and
observed and photographed with a camera-connected Leitz Laborlux
microscope. For each adrenal gland, three unstained autoradiograms
were analyzed by computer-assisted densitometry, as previously de-
tailed [20]. In each autoradiogram, 10 areas of the ZG, outer ZF,
inner ZF and ZR, and adrenal medulla (about 36 000 pixels each)
were analyzed. The density value of the capsule was taken as the
background value.
2.5. Adrenocortical cell cultures
Adrenal glands were gently decapsulated to separate ZG from the
inner zones, then halved and enucleated to eliminate adrenal medulla.
Dispersed ZG and zona fasciculata/reticularis (ZF/R) cells were ob-
tained by sequential collagenase digestion and mechanical disaggrega-
tion [20]. Dispersed ZG cells were suspended in DMEM, containing
10% FCS, 100 U/ml penicillin and 100 Wg/ml streptomycin, and plated
in 35 mm tissue culture dishes. Cells were seeded at a density of
5U105 cells/dish to obtain con£uency after 24 h of culture (secretion
experiments) or at a density of 3U104 cells/dish (growth experiments).
Cells were cultured at 37‡C in a humidi¢ed atmosphere of 95% air/5%
CO2, and employed after 24 h of culture [21].
2.6. Adrenocortical cell secretion
Dispersed ZG and ZF/R cells were put in Medium 199 and Krebs^
Ringer bicarbonate bu¡er with 2% glucose, containing 5 mg/ml HSA.
They were incubated (3U105 cells/ml) with ghrelin (from 10310 to
1036 M), in the presence or absence of 1035 M cyanoketone to pre-
vent further metabolism of pregnenolone [22]. The incubation was
carried out in a shaking bath at 37‡C for 90 min in an atmosphere
of 95% air/5% CO2. Medium was collected, and steroid hormone
concentrations were measured by high pressure liquid chromatogra-
phy (HPLC), as previously described [22]. Pregnenolone was detected
by ultraviolet (UV) absorbance at 290 nm, and other steroid hor-
mones (see Table 2) at 240 nm wavelength, and identi¢ed by compar-
ison of their retention times with those of the standards. Quanti¢ca-
tion of steroid hormones was based on peak area measurement, the
sensitivity of our assay being 1 pmol/ml. Intra- and interassay CVs
were 6.9 and 7.8%, respectively.
Con£uent ZG cell cultures were incubated for 120 min at 37‡C
in fresh DMEM, containing ghrelin (from 10310 to 1036 M) alone
and in the presence of 1039 M ACTH or Ang-II. Other cultures were
incubated in DMEM without any peptide (baseline value). The me-
dium was collected, and aldosterone and corticosterone concentra-
tions were measured, without previous extraction and puri¢cation,
using commercial RIA kits: ALDO CTK2 (IRE-Sorin, Vercelli, Italy;
sensitivity: 14 fmol/ml; intra- and interassay CVs: 7.1 and 8.4%,
respectively); and CTRX-RIA (Eurogeneticx, Milan, Italy; sensitiv-
ity: 73 fmol/ml; intra- and interassay CVs: 7.6 and 9.1%, respec-
tively).
Table 1
RT-PCR primers and PCR products
Primers Sequence Annealing temperature Product size
Ghrelin sense 5P-TTGAGCCCAGAGCACCAGAAA-3P
Ghrelin antisense 5P-AGTTGCAGAGGAGGCAGAAGCT-3P 55‡C 347 bp
GHS-R sense 5P-AGGCAACCTGCTCACTATGCTG-3P
GHS-R antisense 5P-GACAAGGATGACCAGCTTCACG-3P 60‡C 321 bp
GAPDH sense 5P-CCCTTCATTGACCTCAACTA-3P
GAPDH antisense 5P-GCCAGTGAGCTTCCCGTTCA-3P 57‡C 585 bp
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2.7. Adrenocortical cell proliferation
Non-con£uent ZG cell cultures were incubated for 24 h at 37‡C in
fresh DMEM (supplemented with 10% FCS), containing (i) ghrelin
(from 10310 to 1038 M) alone and in the presence of 1038 M ET-1-
[1^31]; (ii) ghrelin (1038 M) alone and in the presence of 1035 M H-
89, 1035 M calphostin-C, 1035 M tyrphostin-23 or 1034 M PD-98059;
and (iii) DMEM alone and with H-89, calphostin-C, tyrphostin-23 or
PD-98059. The concentrations of ET-1[1^31] and the signaling cas-
cade inhibitors were chosen according to Mazzocchi et al. [21]. During
the last 12 h of incubation BrdU was added to the culture medium to
a ¢nal concentration of 20 mg/ml [21]. Cultures were ¢xed in 4%
paraformaldehyde for 30 min, and BrdU-positive (S-phase) cells
were detected using the cell proliferation kit of Amersham Pharmacia
(Aylesbury, UK). The percentage of positive cells (proliferation index)
was evaluated by counting 3000 cells per dish, and six dishes for each
experimental point were employed.
2.8. Adrenocortical cell apoptosis
Non-con£uent ZG cell cultures were incubated for 24 h at 37‡C in
fresh DMEM (supplemented or not with 10% FCS), containing ghre-
lin (from 10310 to 1036 M). Other cultures were incubated in DMEM
without ghrelin (baseline value). Cultures were ¢xed in 4% para-
formaldehyde for 30 min, and apoptotic cells were detected using
the TACS Klenow in situ apoptosis detection kit of Sigma. The per-
centage of positive cells (apoptotic index) was evaluated by counting
3000 cells per dish, and six dishes for each experimental point were
employed.
2.9. Tyrosine kinase (TK) and mitogen-activated protein kinase
(MAPK) activity
Dispersed ZG cells were put in Medium 199 and Krebs^Ringer
bicarbonate bu¡er with 2% glucose, containing 5 mg/ml BSA. They
were incubated with ghrelin (from 10310 to 1036 M) or without ghre-
lin (baseline value). Other preparations were preincubated for 30 min
with 1035 M tyrphostin-23 or 1034 M PD-98059, and then exposed or
not to ghrelin (1038 M). The incubation was carried out in a shaking
bath at 37‡C for 15 min, and was stopped by two quick washes with
ice-cold PBS. Dispersed cells were lysed and homogenized, as previ-
ously described [23]. Homogenates were centrifuged at 4‡C at 800Ug
for 10 min, and then at 12 000Ug for 15 min. Supernatants were
removed, the protein concentration was determined by the Lowry
method, and then stored at 380‡C. TK activity was assayed, using
poly(Glu4,Tyr1) as substrate [24]. MAPK activity was measured using
anti-MAPK p42/p44 polyclonal antibody and myelinic basic protein
as substrate [25].
2.10. Statistics
Data were expressed as meansIS.E.M. of six separate experiments.
Their statistical comparison was done by analysis of variance
(ANOVA), followed by Duncan’s multiple range test.
3. Results and discussion
RT-PCR demonstrated sizeable expression of ghrelin and
GHS-R mRNAs in the rat adrenal cortex (Fig. 1), as well as
in the hypothalamus and testis (data not shown). RIA de-
tected high concentrations of ghrelin-IR in the adrenal cortex
and hypothalamus and low concentrations in the testis (Fig.
2). Autoradiography evidenced abundant [125I]ghrelin binding
sites in the adrenal gland, which were located in the outer
portion of the cortex, and to a lesser extent in the adrenal
medulla (Fig. 3A). The binding was completely displaced
not only by cold ghrelin (Fig. 3B), but also by the selective
GHS-R ligand hexarelin [26] (data not shown). The quantita-
tive densitometric analysis of autoradiograms con¢rmed
these qualitative observations (Fig. 4), thereby indicating
that [125I]ghrelin binding sites are GHS-Rs. Taken together
these ¢ndings, in addition to con¢rming the presence of ghre-
lin in the rat hypothalamus and testis [4,15], provide evidence
that ghrelin is expressed as mRNA and protein in the rat
adrenal cortex. A previous investigation did not demonstrate
ghrelin mRNA expression in the rat adrenals [18]. At present,
we are unable to provide a reasonable explanation of this
discrepancy, although we wish to stress that di¡erent strains
of rats (Sprague^Dawley versus Wistar rats) were used. More-
over, our study con¢rms that rat adrenals, like human glands
[16,17], possess GHS-Rs [18], and provides the ¢rst evidence
that ghrelin binding sites are mainly located in the ZG and
outer ZF.
The HPLC assay (Table 2) demonstrated that ghrelin did
not evoke any signi¢cant change in the basal secretion of
pregnenolone, progesterone, 11-deoxycorticosterone, cortico-
Table 2
Lack of e¡ect of ghrelin on basal steroid hormone secretion from dispersed rat adrenocortical cells
Baseline Ghrelin 10310 M Ghrelin 1038 M Ghrelin 1036 M
ZG cells
Pregnenolone 589.2I 160.7 685.1I 248.5 554.2I 191.6 515.8I 185.2
Progesterone 128.8I 36.8 101.8I 36.9 140.5I 51.2 139.4I 45.7
11-Deoxycorticosterone 8.9 I 4.3 10.7I 3.8 9.8 I 3.7 8.1 I 2.9
Corticosterone 99.0I 23.1 88.5I 22.6 104.1I 30.9 105.7I 39.4
18-Hydroxycorticosterone 25.7I 6.3 20.4I 7.1 33.2I 11.5 28.1I 9.4
Aldosterone 49.5I 19.9 55.6I 15.8 41.8I 14.5 50.8I 18.7
ZF/R cells
Pregnenolone 609.1I 156.7 559.5I 175.2 670.8I 199.6 635.4I 207.5
Progesterone 121.5I 33.7 148.7I 49.0 135.6I 41.2 118.7I 30.8
11-Deoxycorticosterone 81.4I 10.9 70.5I 15.6 75.7I 12.9 85.1I 19.5
Corticosterone 286.2I 94.3 315.4I 111.5 254.8I 100.1 306.4I 89.7
18-Hydroxycorticosterone 4.4 I 3.8 ND 8.2I6.7 ND
Aldosterone ND ND ND ND
Values are expressed as pmol/106 cellsWh, and are meansIS.D. (n=6). ND, not detectable. Di¡erences among groups are not signi¢cant.
Fig. 1. Ethidium bromide-stained 2% agarose gel showing cDNA
ampli¢ed with rat speci¢c primers from RNA of three exemplary
rat adrenal cortices. Lane 1 was loaded with 200 ng of a size
marker (marker VIII; Roche Molecular Biochemicals, Mannheim,
Germany). The ampli¢ed fragments were of the expected sizes: 347
bp for ghrelin, 321 bp for GHS-R, and 585 bp for GAPDH. No
ampli¢cation of PCR mixture without prior RT of the mRNAs is
shown as negative control.
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sterone, 18-hydroxycorticosterone and aldosterone from dis-
persed rat ZG and ZF/R cells. As expected, ZG cell cultures
released high amounts of aldosterone and displayed a secre-
tory response to both ACTH and Ang-II, while ZF/R cell
cultures mainly produced corticosterone and were responsive
only to ACTH. Again, RIA showed that ghrelin did not sig-
ni¢cantly alter either basal or agonist-stimulated secretion of
aldosterone and corticosterone from cultured cells (Fig. 5).
Hence, ghrelin, within the range of concentrations used, af-
fects neither basal early and late steps of steroid synthesis nor
agonist-stimulated late steps. This observation is in keeping
with the reported lack of e¡ect of ghrelin on rat adrenal cor-
ticosterone production [18], and indicates that adrenal ghrelin
receptors behave di¡erently from those of rat Leydig cells,
where ghrelin has been found to decrease human chorionic
gonadotropin- and cyclic AMP-stimulated testosterone secre-
tion through a mechanism probably involving down-regula-
tion of steroid acute regulatory protein, P450 cholesterol side
chain cleavage and 3L-hydroxysteroid dehydrogenase (i.e. by
inhibiting agonist-stimulated early steps of steroid synthesis)
[15].
As discussed above, the ghrelin receptors are mainly present
in the ZG, which is the layer involved in the maintenance of
the adrenal growth [27]. Thus we examined the e¡ects of
ghrelin on the growth of cultured ZG cells. Ghrelin (1038
and 1036 M) markedly raised basal, but not ET-1[1^31]-
enhanced, proliferation index of ZG cell cultures. Conversely,
ghrelin did not modify apoptotic index of ZG cells either
cultured in FCS-supplemented or FCS-free medium (Fig. 6).
It is to be noted that the observed proliferogenic action of
ghrelin appears to con£ict with the results of a previous study,
which showed that this peptide causes a marked inhibition of
the proliferative activity of three di¡erent human breast car-
cinoma cell lines [28]. However, they are in accord with the
reported stimulating action of ghrelin on cardiomyocyte H9c2
and prostate cancer PC3 cell lines [29,30]. The possibility that
the proliferogenic action of ghrelin on cultured ZG may be
mediated by a novel receptor other than GHS-R is unlikely in
light of the ¢ndings that the selective GHS-R agonist hexa-
relin (i) completely eliminates [125I]ghrelin binding in the ZG
(see above), and (ii) mimics the e¡ect of ghrelin on ZG cell
proliferation index (preliminary data not shown).
The 1038 M ghrelin-induced rise in ZG cell proliferation
index was not a¡ected by either 1035 M H-89 or 1035 M
Fig. 2. Ghrelin-IR concentration in rat hypothalamus, adrenal cor-
tex and testis. Bars enclose values of the six samples (gray circles)
and their meansIS.D. (black circles).
Fig. 3. Autoradiograms of hematoxylin-eosin-stained frozen sections
of rat adrenal gland incubated with 1038 M [125I]ghrelin. Binding is
present in both outer cortex and medulla of the gland (A), and is
completely displaced by 1036 M cold ghrelin (B). c, Gland capsule;
AM, adrenal medulla; ZF, zona fasciculata; ZG, zona glomerulosa;
ZR, zona reticularis. 70U.
Fig. 4. Evaluation by quantitative densitometry of [125I]ghrelin bind-
ing in the rat adrenal cortex and medulla (total binding, TB), and its
displacement by cold ghrelin and hexarelin. AM, adrenal medulla;
ZF, zona fasciculata; ZG, zona glomerulosa; ZR, zona reticularis.
Data are meansIS.E.M. (n=3). *P6 0.01 versus the background
(BG) value; aP6 0.01 versus the respective TB value.
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calphostin-C, but was abolished by both 1035 M tyrphostin-
23 and 1034 M PD-98059 (Fig. 7). Ghrelin (1038 and 1036 M)
signi¢cantly enhanced TK and MAPK p42/p44 activities (by
about 2.5- and 3.1-fold, respectively) (Fig. 8, upper panel).
Preincubation with 1035 M tyrphostin-23, but not 1034 M
PD-98059, blocked the ghrelin (1038 M)-induced stimulation
of TK activity. In contrast, the ghrelin-evoked stimulation
of MAPK activity was annulled by both tyrphostin-23 and
PD-98059 (Fig. 8, lower panel).
These ¢ndings demonstrate that ghrelin, like ET-1[1^31]
[21], exerts its growth-promoting action on cultured rat ZG
cells by activating the TK^MAPK signaling pathway (Fig. 9),
and this is in keeping with the lack of additivity between
Fig. 5. Lack of e¡ect of ghrelin on basal and agonist-stimulated
aldosterone and corticosterone secretion from rat ZG cell (upper
panel) and ZF/R cell cultures (lower panel), respectively. Bars
are meansIS.E.M. (n=6). aP6 0.01 versus the respective baseline
value.
Fig. 6. E¡ect of ghrelin on basal and stimulated proliferation (left
panel) and apoptotic rate (right panel) of cultured rat ZG cells.
Bars are meansIS.E.M. (n=6). *P6 0.01 versus the respective con-
trol value; aP6 0.01 versus the respective baseline value.
Fig. 7. E¡ects of H-89 (1035 M), calphostin-C (1035 M), tyrphos-
tin-23 (1035 M) and PD-98059 (1034 M) on basal and ghrelin (1038
M)-stimulated proliferation rate of cultured rat ZG cells. Bars are
meansIS.E.M. (n=6). *P6 0.01 versus the respective control
value; aP6 0.01 versus the respective baseline value.
Fig. 8. E¡ects of ghrelin on basal TK and MAPK p42/p44 activities
of dispersed rat ZG cells (upper panels), and of the preincubation
with tyrphostin-23 (1035 M) or PD-98059 (1034 M) on basal and
ghrelin (1038 M)-stimulated activities (lower panels). Bars are means
IS.E.M. (n=6). *P6 0.01 versus the respective control value;
aP6 0.01 versus the respective baseline value.
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ghrelin and ET-1[1^31] proliferogenic e¡ects. This contention
is based on the following pieces of evidence: (i) the TK in-
hibitor tyrphostin-23 [31] and the MEK1 inhibitor PD-98059
[32] block the ghrelin-induced rise in the number of BrdU-
positive ZG cells ; (ii) these inhibitors per se do not elicit any
apparent e¡ect on basal DNA synthesis rate, thereby ruling
out the possibility that these results were due to a non-speci¢c
toxic e¡ect on cultured ZG cells ; (iii) ghrelin stimulates both
TK and MAPK activity, and the e¡ect is reversed by tyrphos-
tin-23 and PD-98059 at the concentrations annulling the ZG
proliferogenic action of the peptide; and (iv) tyrphostin-23
blocks the ghrelin-induced stimulation of MAPK activity.
The TK receptor is well known to be involved in the acti-
vation of p42/p44 MAPKs [33^35]. However, many lines of
evidence indicate that TK, behaving as a G protein-coupled
receptor, can activate MAPK cascade via both protein kinase
(PK) C- [35^37] and PKA-dependent pathways [37,38]. Ac-
cordingly, cyclic AMP and Ang-II were found to activate
MAPK and to enhance proliferation of ZG cells via a
PKA- and a PKC-dependent pathway, respectively [39,40].
Likewise, ET-1[1^31] has been reported to exert its prolifero-
genic action on cultured ZG cells via two independent path-
ways involving both TK-dependent and PKC-dependent
MAPK cascades [21]. In contrast, our present results make
it unlikely that either PKA or PKC cascades play a relevant
role in the growth e¡ect of ghrelin on adrenals, in as much as
neither the PKA inhibitor H-89 [41] nor the PKC inhibitor
calphostin-C [42] are able to blunt the proliferogenic action of
this peptide on cultured ZG cells (Fig. 9). It is to be noted
that this ¢nding is reminiscent of that obtained with adreno-
medullin, a regulatory peptide which has been found to en-
hance rat ZG cell proliferation via a MAPK signaling mech-
anism exclusively dependent on TK activation [23,43].
In summary, the present study indicates that (i) ghrelin and
GHS-R are both expressed in the rat adrenal cortex; (ii) ghre-
lin binding sites are abundant in the outer cortex; (iii) ghrelin
does not a¡ect the secretory activity of rat adrenocortical
cells; (iv) ghrelin stimulates proliferation of cultured ZG cells,
without signi¢cantly a¡ecting apoptotic deletion rate; and (v)
the ZG proliferogenic action of ghrelin involves the TK-de-
pendent activation of the p42/p44 MAPK cascade. In conclu-
sion, our results allow us to include ghrelin in that group of
peptides [44,45] involved in the autocrine^paracrine regulation
of adrenal growth.
References
[1] Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H.
and Kangawa, K. (1999) Nature 402, 656^660.
[2] Howard, A.D., Feighner, S.C., Cully, D.F., Arena, J.P., Libera-
tor, P.A., Rosenblum, C.I., Hamelin, M., Hreniuk, D.L., Palyha,
O.C., Anderson, J., Paress, P.S., Diaz, C., Chou, M., Liu, K.K.,
McKee, K.K., Pong, S.S., Chaung, L.L., Elbrecht, A., Dashke-
vicz, M., Heavens, R., Rigby, M., Sirinathsinghji, D.J.S., Dean,
D.C., Melillo, D.G., Patchett, A.A., Nargund, R., Gri⁄n, P.R.,
De Martino, J.A., Gupta, S.K., Schae¡er, J.M., Smith, R.G. and
Van der Ploeg, L.H.T. (1996) Science 273, 974^977.
[3] McKee, K.K., Palyha, O.C., Feighner, S.D., Hreniuk, D.L., Tan,
C.P., Phillips, M.S., Smith, R.G., Van der Ploeg, L.H.T. and
Howard, A.D. (1997) Mol. Endocrinol. 11, 415^423.
[4] Kojima, M., Hosoda, H., Matsuo, H. and Kangawa, K. (2001)
Trends Endocrinol. Tab. 12, 118^122.
[5] Muccioli, G., Papotti, M., Locatelli, V., Ghigo, E. and Deghen-
ghi, R. (2001) J. Endocrinol. Invest. 24, RC7^RC9.
[6] Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimo-
to, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu,
A., Ogawa, Y., Hosoda, K., Akamizu, T., Kojima, M., Kanga-
wa, K. and Nakao, K. (2000) J. Clin. Endocrinol. Metab. 85,
4908^4911.
[7] Ghigo, E., Arvat, E., Giordano, R., Broglio, F., Gianotti, L.,
Maccario, M., Bisi, G., Graziani, A., Papotti, M., Muccioli,
G., Deghenghi, R. and Camanni, F. (2001) Endocrine 14, 87^93.
[8] Tscho«p, M., Smiley, D.L. and Heiman, M.L. (2000) Nature 407,
908^913.
[9] Wren, A.M., Small, C.J., Ward, H.L., Murphy, K.J., Dakin,
C.L., Taheri, S., Kennedy, A.R., Roberts, G.H., Morgan,
D.G., Gathei, M.A. and Bloom, S.R. (2000) Endocrinology
141, 4325^4328.
[10] Horvath, T.L., Diano, S., Sotonyi, P., Heiman, M. and Tscho«p,
M. (2001) Endocrinology 142, 4163^4169.
[11] Korbonits, M., Kaltsas, G., Perry, L.A., Putignano, P., Gross-
man, A.B., Besser, G.M. and Trainer, P.G. (1999) J. Clin. En-
docrinol. Metab. 84, 2489^2495.
[12] Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fu-
jimiya, M., Katsuura, G., Makino, S., Fujino, M.A. and Kasuga,
M. (2001) Neuroendocrinology 74, 143^147.
[13] Ishizaki, S., Murase, T., Sugimura, Y., Kakiya, S., Yokoi, H.,
Takikawa, K., Arima, H., Miura, Y. and Oiso, Y. (2002) Endo-
crinology 143, 1589^1593.
[14] Date, Y., Nakazato, M., Hashiguchi, S., Dezaki, K., Mondal,
M.S., Hosoda, H., Kojima, M., Kangawa, K., Arima, T., Mat-
suo, H., Yada, T. and Matsukura, S. (2002) Diabetes 51, 124^
129.
[15] Tena-Sempere, M., Barreiro, M.L., Gonza'lez, L.C., Gayta¤n, F.,
Zhang, F.P., Caminos, J.E., Pinilla, L., Casanueva, F.F., Die¤-
guez, C. and Aguilar, E. (2002) Endocrinology 143, 717^725.
[16] Papotti, M., Ghe', C., Cassoni, P., Catapano, F., Deghenghi, R.,
Ghigo, E. and Muccioli, G. (2000) J. Clin. Endocrinol. Metab.
85, 3803^3807.
[17] Gnanapavan, S., Kola, B., Bustin, S.A., Morris, D.G., McGee,
Fig. 9. Simpli¢ed scheme illustrating the main pathways inducing
cell proliferation, the possible locus of action of ghrelin and the
sites of action of inhibitors. Brie£y, tyrosine kinase (TK), by bind-
ing to its agonists, activates Ras, a peptide belonging to a family of
GTP binding proteins. Ras in turn triggers a cascade leading to the
sequential activation of p21-activated kinase (PAK), Raf, MEK1/2
and extracellular (signal) regulated kinases (ERK1/2). ERK1/2 in-
duce the expression, among others, of the c-fos gene, the products
of which associate with other related protein to form the transcrip-
tional factor AP-1. TK may also behave as a G protein-coupled re-
ceptor, which, through the activation of adenylate cyclase (AC) and
phospholipase-C (PLC), leads to the production of protein kinases
(PK)A and C. PKA and PKC can activate MAPK cascade via a
not yet known Ras-independent mechanism. + and 3 symbols near
the arrow heads indicate activation and inhibition, respectively.
FEBS 26966 29-1-03 Cyaan Magenta Geel Zwart
P.G. Andreis et al./FEBS Letters 536 (2003) 173^179178
P., Fairclough, P., Bhattacharyya, S., Carpenter, R., Grossman,
A.B. and Korbonits, M. (2002) J. Clin. Endocrinol. Metab. 87,
2988^2991.
[18] Barreiro, M.L., Pinilla, L., Aguilar, E. and Tena-Sempere, M.
(2002) Eur. J. Endocrinol. 147, 677^688.
[19] Mazzocchi, G., Rossi, G.P., Neri, G., Malendowicz, L.K., Alber-
tin, G. and Nussdorfer, G.G. (1998) FASEB J. 12, 1533^1539.
[20] Belloni, A.S., Rossi, G.P., Andreis, P.G., Neri, G., Albertin, G.,
Pessina, A.C. and Nussdorfer, G.G. (1996) Hypertension 27,
1153^1159.
[21] Mazzocchi, G., Rossi, G.P., Malendowicz, L.K., Champion,
H.C. and Nussdorfer, G.G. (2000) FEBS Lett. 487, 194^198.
[22] Neri, G., Malendowicz, L.K., Andreis, P.G. and Nussdorfer,
G.G. (1993) Endocrinology 133, 511^514.
[23] Andreis, P.G., Markowska, A., Champion, H.C., Mazzocchi, G.,
Malendowicz, L.K. and Nussdorfer, G.G. (2000) Endocrinology
141, 2098^2104.
[24] Nichols, M.R. and Morimoto, B.H. (1999) Arch. Biochem. Bio-
phys. 366, 224^230.
[25] Hayashida, W., Horiuchi, M. and Dzau, V.J. (1996) J. Biol.
Chem. 271, 21985^21992.
[26] Guillaume, V., Magnan, E., Cataldi, M., Dutour, A., Sauze, N.,
Renard, M., Raza¢ndraibe, H., Conte-Devolx, B., Deghenghi,
R., Lenaerts, V. and Oliver, C. (1994) Endocrinology 135,
1073^1076.
[27] Nussdorfer, G.G. (1986) Int. Rev. Cytol. 98, 1^405.
[28] Cassoni, P., Papotti, M., Ghe¤, C., Catapano, F., Sapino, A.,
Graziani, A., Deghenghi, R., Reissmann, T., Ghigo, E. and Muc-
cioli, G. (2001) J. Clin. Endocrinol. Metab. 86, 1738^1745.
[29] Je¡ery, P.L., Herington, A.C. and Chopin, L.K. (2002) J. Endo-
crinol. 172, R7^R11.
[30] Pettersson, P.L., Muccioli, G., Granata, R., Deghenghi, R., Ghi-
go, E., Ohlsson, C. and Isgaard, J. (2002) J. Endocrinol. 175,
201^209.
[31] Levitzi, A. and Gilon, C. (1991) Trends Pharmacol. Sci. 12, 171^
174.
[32] Alessi, D.R., Cuenda, A., Cohen, P., Dudly, D.T. and Saltiel,
A.R. (1995) J. Biol. Chem. 270, 27489^27494.
[33] Campbell, J.S., Seger, R., Graves, J.D., Graves, L.M., Jensen,
A.M. and Krebs, E.G. (1995) Recent Progr. Horm. Res. 50, 131^
159.
[34] Van Biesen, T., Luttrel, L.M., Hawes, B.E. and Lefkowitz, R.J.
(1996) Endocr. Rev. 17, 698^714.
[35] Fanger, G.R. (1999) Histol. Histopathol. 14, 887^894.
[36] Hawes, B.E., Van Biesen, T., Koch, W.J., Luttrel, L.M. and
Lefkowitz, R.J. (1995) J. Biol. Chem. 270, 17148^17153.
[37] Han, X.B. and Conn, P.M. (1999) Endocrinology 140, 2241^
2251.
[38] Wan, Y. and Huang, X.Y. (1998) J. Biol. Chem. 273, 14533^
14537.
[39] Miyamoto, N., Seo, H., Kanda, K., Hidaka, H. and Masui, N.
(1992) Endocrinology 130, 3231^3236.
[40] Tian, Y., Smith, R.D., Balla, T. and Catt, K.J. (1998) Endocri-
nology 139, 1801^1809.
[41] Chijwa, T., Mishima, A., Hagiwara, M., Sano, M., Hayashi, K.,
Inoue, T., Naito, K., Toshioka, T. and Hidaka, H. (1990) J. Biol.
Chem. 265, 5267^5272.
[42] Kobayashi, E., Ando, K., Nakano, H., Iida, T., Ohno, H.,
Morimoto, M. and Tamaoki, T. (1989) J. Antibiot. 42, 1470^
1474.
[43] Semplicini, A., Ceolotto, G., Baritono, E., Malendowicz, L.K.,
Andreis, P.G., Sartori, M., Rossi, G.P. and Nussdorfer, G.G.
(2001) J. Hypertens. 19, 599^602.
[44] Nussdorfer, G.G. (1996) Pharmacol. Rev. 48, 495^530.
[45] Delarue, C., Contesse, V., Lenglet, S., Sicard, F., Perraudin, V.,
Lefebvre, H., Kodjo, M., Leboulenger, F., Yon, L., Gallo-Payet,
N. and Vaudry, H. (2001) Rev. Endocr. Metab. Disord. 2, 253^
267.
FEBS 26966 29-1-03 Cyaan Magenta Geel Zwart
P.G. Andreis et al./FEBS Letters 536 (2003) 173^179 179
